Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMDTGWQ)

Drug Name
GMI-1271 Drug Info
Synonyms Uproleselan
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 3 [1]
Multiple myeloma 2A83 Phase 1 [2]
Cross-matching ID
PubChem CID
71600085
CAS Number
CAS 1983970-12-2
TTD Drug ID
DMDTGWQ

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
E-selectin (SELE) TTAU4D6 LYAM2_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
E-selectin (SELE) DTT SELE 5.194 3.307 3.104 5.907
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Acute myeloid leukaemia
ICD Disease Classification 2A60
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
E-selectin (SELE) DTT SELE 6.43E-04 0.02 0.12
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03616470) Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of glycomimetics.